L

Laboratorios Richmond SACIF
BCBA:RICH

Watchlist Manager
Laboratorios Richmond SACIF
BCBA:RICH
Watchlist
Price: 1 935 ARS 0.52% Market Closed
Market Cap: 156.3B ARS

Net Margin

13.5%
Current
Improving
by 9.1%
vs 3-y average of 4.4%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
13.5%
=
Net Income
14.2B
/
Revenue
105.9B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
13.5%
=
Net Income
ARS14.2B
/
Revenue
105.9B

Peer Comparison

Country Company Market Cap Net
Margin
AR
Laboratorios Richmond SACIF
BCBA:RICH
155.4B ARS
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
528.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
221.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
267.9B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.6B USD
Loading...

Market Distribution

Higher than 72% of companies in Argentina
Percentile
72nd
Based on 129 companies
72nd percentile
13.5%
Low
-11 625% — -2.9%
Typical Range
-2.9% — 12%
High
12% — 19 017.3%
Distribution Statistics
Argentina
Min -11 625%
30th Percentile -2.9%
Median 7.9%
70th Percentile 12%
Max 19 017.3%

Laboratorios Richmond SACIF
Glance View

Market Cap
156.3B ARS
Industry
Pharmaceuticals

Laboratorios Richmond SACIF manufactures pharmaceutical products. The company is headquartered in Buenos Aires, Buenos Aires. The company went IPO on 2017-12-22. The firm's product categories include: Antiviral, under the brands Ciganclor, Lazinevir, Leuzan, Mivuten, Probirase, Protease, Selmivir, Trivenz, Virontar, Virontar N, Virontar 600, Vuclodir, Zepril, Zetavudin, and Zetrotax; Oncologi and Oncohematologic, under the brands Bemux, Capecit, Doxetal, Drifen, Espasevit, Fontrax, Gezt, and Monofer, among others; Cardiovascular, under the brands Amze 5, Amze 10, Antiplaq, Bilip 10, Bilip 20, Tacardia, and Timezol 20, among others; Neuropsychiatric, under the brands Dalam 15, Dolofrix 10, Donepes 5, and Prilben 10, among others, as well as Hospital, under the brands Amidiaz, Dalam, and Fentax, among others.

RICH Intrinsic Value
3 938.94 ARS
Undervaluation 51%
Intrinsic Value
Price
L
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
13.5%
=
Net Income
14.2B
/
Revenue
105.9B
What is Laboratorios Richmond SACIF's current Net Margin?

The current Net Margin for Laboratorios Richmond SACIF is 13.5%, which is above its 3-year median of 4.4%.

How has Net Margin changed over time?

Over the last 3 years, Laboratorios Richmond SACIF’s Net Margin has increased from 5.8% to 13.5%. During this period, it reached a low of -27.8% on Dec 31, 2023 and a high of 26% on Dec 31, 2024.

Back to Top